COVID-19: Pharmidex Contingency Plan
March 19, 2020

Pharmidex are taking all the necessary steps to ensure the progression of client studies during these difficult time.

COVID-19: Pharmidex Contingency Plan


We are taking all necessary steps to ensure that studies proceed, while preserving the health and safety of staff. Summary of key steps taken at Pharmidex:


- Following the relevant guidelines issued by Public Health England.


- Limiting access to only essential people in our laboratories and cancelling/rescheduling all non-critical visitors. All visitors must confirm COVID-19 status prior to arrival.


- Cancelled all non-essential business travel.


- Closely communicating with suppliers regarding the status of their inventories and their business continuity plans and identifying alternate sources for supplies.


- Implemented strict sanitization practices to prevent cross contamination between staff, including providing our staff with resources and up-to-date information and guidance.


- To prevent the potential spread of the infection amongst employees, staff will declare any potential close contact with infected individuals and follow the relevant health guidelines.


- Our operations team will ensure adequate staffing cover so as not to compromise client studies.


We will keep you updated if the situation changes resulting in any impact on progression of your projects.


Best wishes to everyone during these tough times.

December 16, 2025
We are pleased to share that Ian Knowles and Martin Barrett will attend Pharmacology 2025, organized by The British Pharmacological Society (BPS), at the ICC Belfast from 16–18 December 2025. They will host a Pharmidex exhibition stand, showcasing our key services and their importance in drug discovery and development. Ian and Martin will be delighted to meet attendees, exchange ideas, and explore new collaboration opportunities. Come and say hello!
December 8, 2025
Head of Respiratory at Pharmidex , Ian Knowles will be attending the Drug Delivery to the Lungs Conference (DDL) on 10–12 December 2025 at the Edinburgh International Conference Centre. DDL brings together global leaders in pulmonary and respiratory drug delivery, and Ian looks forward to meeting fellow attendees, exploring collaborations, and discussing how Pharmidex can support and accelerate drug discovery and development across industry and academia. If you’ll be there too, feel free to reach out we look forward to building new connections and advancing innovation together.
December 3, 2025
Pharmidex is pleased to announce that Dr. Mo Alavijeh (FRSC, FRSM) and Janette Dalay Robertson will attend the “Recent Clinical Candidates and SMR Award Meeting” this Thursday, 4 December 2025. If you’re attending, we’d be happy to connect!
More Posts